Dupixent is one of the most-frequently prescribed drugs for eczema and asthma, but scientists believe that taking it could put patients at risk for cutaneous T-cell lymphoma, a rare type of cancer that can attack skin tissue and blood cells.
If you or a loved one has been diagnosed with cutaneous T-cell lymphoma after taking Dupixent, you could be entitled to significant compensation.
Here is what you need to know about:
Dupixent And CTCL
Dupixent is a type of biologic medication that is designed to work from the inside out.
After you take Dupixent, the medication will bind to a set of protein receptors. It is, in fact, the first-ever medication engineered to target the IL-4 receptor alpha to inhibit immune system signaling. By blocking certain immune system pathways, Dupixent can help reduce inflammation associated with eczema outbreaks and asthma attacks.
However, a growing body of research now indicates that Dupixent could have a very serious downside. According to a recent series of reports, people who take Dupixent appear to have a significantly higher likelihood of developing cutaneous T-cell lymphoma than patients who take other medications. Cutaneous T-cell lymphoma, or CTCL, is a rare type of cancer that can affect both the skin and the blood.
Nobody understands the exact nature of the relationship between Dupixent and CTCL. One theory suggests that, because eczema symptoms often overlap with those of early-stage CTCL, taking Dupixent can effectively “mask” the emergence of cancer, making it more difficult to obtain an accurate diagnosis. Since cancer can metastasize and spread to other parts of the body, this presents a serious and potentially life-threatening risk.
Other researchers have speculated that Dupixent could simply make cancer symptoms more apparent; alternatively, this medication may “accelerate” the spread of cutaneous T-cell lymphoma, leading it to become more aggressive.
Your Rights After A CTCL Diagnosis
Medical researchers have only just begun investigating the link between Dupixent and CTCL, but that does not mean that you have to wait to take action. Under state and federal law, pharmaceutical companies are bound by a wide range of legal responsibilities. In general, drug-makers must proactively:
- Identify potential side effects and complications;
- Document potential side effects and complications; and
- If found valid, warn the public of these side effects and complications.
Most patients who take Dupixent were never warned that their medication could cause, accelerate, or mask the emergence of cutaneous T-cell lymphoma. This means that companies like Sanofi and Regeneron, the manufacturers of Dupixent, could be held liable for any resulting injuries.
You could have standing to file a personal injury lawsuit if:
- You were prescribed Dupixent for atopic dermatitis, asthma, or another approved use;
- You took Dupixent responsibly and in accordance with your doctor’s instructions; and
- You were diagnosed with cutaneous T-cell lymphoma after taking Dupixent.
Compensation In A Dupixent CTCL Lawsuit
Your damages are compensation for losses you have sustained as the direct result of a Dupixent-related cancer diagnosis. Depending on the circumstances of your case, you could receive damages for:
- Paid hospital bills;
- The costs of future care;
- Physical rehabilitation;
- Reconstructive surgery;
- Lost income from work;
- Emotional pain and suffering;
- Physical pain and suffering;
- Diminished earning potential;
- Loss of enjoyment; and
- Wrongful death.
If you think that you could have a case, call Jed Dietrich, Esq., today at 1-866-529-5334 to speak to a New York Dupixent cancer lawyer and schedule your 100% free, no-obligation consultation as soon as possible.